Navigating New Waters for Advanced or Recurrent Endometrial Cancer

Faculty

Richard T. Penson, MD, MRCP
Moderator
Physician, Mass General Brigham
Associate Professor, Harvard Medical School
Institutional Review Board (IRB) Chair, Dana Farber Harvard Cancer Center
Boston, MA
Paula J. Anastasia, MN, RN, AOCN
GYN Oncology Advanced Practice Nurse
UCLA Health
Los Angeles, CA

Statement of Need

Patient prognosis for endometrial cancer (EC) is highly benefited by molecular profiling, and national and international guidelines robustly recommend its integration into practice. Characterization of DNA mismatch repair (MMR) status identifies clinically significant molecular subtypes. This information assists clinicians in creating treatment plans tailored to specific tumor phenotypes and individual needs, including those patients with advanced and recurrent EC. Despite ringing endorsements and clear clinical applications, however, molecular profiling remains underutilized due to logistical challenges and a lack of clinician confidence. It is imperative that clinicians, in collaboration with the multidisciplinary team (MDT), become knowledgeable about this exciting technique and utilize it to enhance treatment decisions for patients.

In this CE Concepts live webcast, expert faculty will guide learners through integration of appropriate, guideline-directed molecular profiling strategies in the EC risk assessment and treatment decision process. Faculty will also assess the latest efficacy and safety data for the treatment of EC with learners and develop guideline-concordant and patient-specific therapeutic plans for patients with newly diagnosed advanced or recurrent EC that incorporate MDT collaboration strategies.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Integrate appropriate, guideline-directed molecular profiling strategies in the EC risk assessment and treatment decision process
  • Assess the latest efficacy and safety data for the treatment of EC factoring in updates to guidelines
  • Develop a guideline-concordant and patient-specific therapeutic plan for patients with newly diagnosed advanced or recurrent EC utilizing MDT collaboration strategies

Financial Support

Supported by an educational grant from AstraZeneca Pharmaceuticals and Merck Sharp & Dohme LLC a subsidiary of Merck & Co., Inc.

Target Audience

Gynecologic oncologists, pathologists, gynecologists, physician associates (PAs), nurse practitioners (NPs), nurses, and other HCPs part of the MDT.

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center

This activity is designated for 1.00 contact hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

American Nurses Credentialing Center with ILNA

This activity is designated for 1.00 contact hours.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:

PAs (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 09/17/2024. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Penson reports the following financial relationships:

Advisory Board: Aadi Bioscience; AstraZeneca; GSK; ImmunoGen, Inc.; Merck & Co., Inc.; Mersana Therapeutics, Inc.; Novacure; Roche; Sutro Biopharma, Inc.; and Vascular Biogenics

Consultant: Serves on DSMBs for AstraZeneca; EQRx; and Roche

Research Support: Intuitional research funding (as PI) for Array BioPharma Inc.; AstraZeneca; Eisai Inc.; Genentech, Inc.; and Vascular Biogenics

Other financial or material support: Royalties: BMJ Publishing Group Ltd; Elsevier; UpToDate, Inc.; Wolters Kluwer Health and Wiley-Blackwell. Payment for educational events: Research to Practice; ExpertConnect; and ReachMD

Ms. Anastasia reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Katherine Lee, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

WC-084-071724-90

Call us at 859-260-1717  •  info@ceconcepts.com

Navigating New Waters for Advanced or Recurrent Endometrial Cancer
Activity Date: 07/17/2024 at 6:30 PM EST